Tahreen Taj
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tahreen Taj has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Biplab Debnath
Department of Pharmaceutical Technology Bharat Technology Howrah West Bengal India
2 shared publications - Aakriti Patel
UMU School of Pharmacy, Usha Martin University, at Village Narayansoso, Ranchi, India
1 shared publication - Abdulkhaliq J. Alsalman
Department of Clinical Pharmacy, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia
1 shared publication - Amlan Bishal
Department of Pharmaceutical Technology, Bharat Technology, Uluberia, Howrah, 711316, India | Department of Pharmaceutical Technology, Maulana Abul Kalam Azad University of Technology, West Bengal, Nadia, 741249, India
1 shared publication - Haleema Shahin D.H.
Department of Pharmacology, Yenepoya Pharmacy College and Research Centre Yenepoya (Deemed to be) University Mangalore India
1 shared publication - Hiranmoy Mondal
Department of Pharmaceutical Technology, Bharat Technology, Banitabla, Uluberia, Howrah, India
1 shared publication
Latest Publications
- 31 March 2026
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 40 (1) , 89
AI-driven drug–target interaction prediction: current progress, challenges, and future roadmap for precision medicine
Drug–target interactions (DTIs) are fundamental to drug discovery, development, and repositioning. However, experimental methods for DTI identification are often constrained by high costs, time demands, and scalability issues, prompting a shift toward computational approaches. This review systematically explores recent advancements in computational DTI prediction, encompassing ligand-based, target-based, network-based, machine learning (ML), deep learning (DL), and hybrid multi-omics models. Ligand-based techniques, such as QSAR and pharmacophore modeling, offer structure–activity insights but require known ligands. Target-based methods rely on molecular docking and binding site prediction, yet often suffer from incomplete or unknown protein structures. Network-based strategies utilize bipartite and heterogeneous graphs integrated with protein–protein interaction (PPI) networks to infer novel DTIs. ML and DL methods especially graph neural networks and Transformer-based models have significantly improved prediction accuracy by leveraging chemical, biological, and omics features. Notably, hybrid models that integrate genomics, transcriptomics, proteomics, and interactomics data offer a systems biology perspective, enabling context-specific and personalized predictions. Key databases, like DrugBank, ChEMBL, and Binding DB, and computational tools such as Deep Purpose, NeoDTI, and FusionDTI, exemplify the latest advances in DTI prediction. Validation strategies are discussed through contemporary case studies. While substantial progress has been made, key challenges remain, including data sparsity, model interpretability, and generalization. Looking forward, emerging trends such as federated learning, AlphaFold-based docking, and quantum simulations are poised to further transform the field. This review emphasizes the importance of interdisciplinary integration and ethical frameworks, charting a roadmap for future DTI research and its translational applications in precision medicine. Graphical abstract Overview of machine-learning based approaches for predicting drug–target interactions using integrated drug, target, and interaction databases, highlighting supervised and semi-supervised learning frameworks and their key methodological subclasses
- 31 March 2026
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 40 (1) , 89
AI-driven drug–target interaction prediction: current progress, challenges, and future roadmap for precision medicine
Drug–target interactions (DTIs) are fundamental to drug discovery, development, and repositioning. However, experimental methods for DTI identification are often constrained by high costs, time demands, and scalability issues, prompting a shift toward computational approaches. This review systematically explores recent advancements in computational DTI prediction, encompassing ligand-based, target-based, network-based, machine learning (ML), deep learning (DL), and hybrid multi-omics models. Ligand-based techniques, such as QSAR and pharmacophore modeling, offer structure–activity insights but require known ligands. Target-based methods rely on molecular docking and binding site prediction, yet often suffer from incomplete or unknown protein structures. Network-based strategies utilize bipartite and heterogeneous graphs integrated with protein–protein interaction (PPI) networks to infer novel DTIs. ML and DL methods especially graph neural networks and Transformer-based models have significantly improved prediction accuracy by leveraging chemical, biological, and omics features. Notably, hybrid models that integrate genomics, transcriptomics, proteomics, and interactomics data offer a systems biology perspective, enabling context-specific and personalized predictions. Key databases, like DrugBank, ChEMBL, and Binding DB, and computational tools such as Deep Purpose, NeoDTI, and FusionDTI, exemplify the latest advances in DTI prediction. Validation strategies are discussed through contemporary case studies. While substantial progress has been made, key challenges remain, including data sparsity, model interpretability, and generalization. Looking forward, emerging trends such as federated learning, AlphaFold-based docking, and quantum simulations are poised to further transform the field. This review emphasizes the importance of interdisciplinary integration and ethical frameworks, charting a roadmap for future DTI research and its translational applications in precision medicine. Graphical abstract Overview of machine-learning based approaches for predicting drug–target interactions using integrated drug, target, and interaction databases, highlighting supervised and semi-supervised learning frameworks and their key methodological subclasses
- 3 January 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 690, 126545
Oleosomes as emerging Next-Generation carrier for topical drug delivery
- 3 January 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 690, 126545
Oleosomes as emerging Next-Generation carrier for topical drug delivery
- Open Access
Insights into the Protective Effects of Thymoquinone against Toxicities Induced by Chemotherapeutic Agents
The drugs used to treat cancer not only kill fast-growing cancer cells, but also kill or slow the growth of healthy cells, causing systemic toxicities that lead to altered functioning of normal cells. Most chemotherapeutic agents have serious toxicities associated with their use, necessitating extreme caution and attention. There is a growing interest in herbal remedies because of their pharmacological activities, minimal side effects, and low cost. Thymoquinone, a major component of the volatile oil of Nigella sativa Linn, also known as black cumin or black seeds, is commonly used in Middle Eastern countries as a condiment. It is also utilized for medicinal purposes and possesses antidiabetic, anti-cancer, anti-inflammatory, hepatoprotective, anti-microbial, immunomodulatory, and antioxidant properties. This review attempts to compile the published literature demonstrating thymoquinone’s protective effect against chemotherapeutic drug-induced toxicities.
Open AccessInsights into the Protective Effects of Thymoquinone against Toxicities Induced by Chemotherapeutic Agents
The drugs used to treat cancer not only kill fast-growing cancer cells, but also kill or slow the growth of healthy cells, causing systemic toxicities that lead to altered functioning of normal cells. Most chemotherapeutic agents have serious toxicities associated with their use, necessitating extreme caution and attention. There is a growing interest in herbal remedies because of their pharmacological activities, minimal side effects, and low cost. Thymoquinone, a major component of the volatile oil of Nigella sativa Linn, also known as black cumin or black seeds, is commonly used in Middle Eastern countries as a condiment. It is also utilized for medicinal purposes and possesses antidiabetic, anti-cancer, anti-inflammatory, hepatoprotective, anti-microbial, immunomodulatory, and antioxidant properties. This review attempts to compile the published literature demonstrating thymoquinone’s protective effect against chemotherapeutic drug-induced toxicities.